| Shares Outstanding | 7,099,739,773 shares |
| Insider Shares | 31,044,333 shares |
| Insider Ownership | 0.44 % |
| Total Insiders | 6 |
Insider Sentiment Score
The Insider Sentiment Score finds the companies being bought by corporate insiders.
It is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of insider accumulation. The scoring model uses a combination of the net number of insiders buying the prior 90 days, the total shares bought as a percentage of float, and the total shares owned by insiders. The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average.
Update Frequency: Daily
See Insiders Top Picks, which provides a list of companies with highest insider accumulation.
Officer Sentiment Score
The Officer Sentiment Score finds companies being bought by Corporate Officers.
By definition Corporate Officers are Corporate Insiders, but unlike some of the other Insiders (10% Shareholders and Board Members), Officers work for the company on a daily basis, and they user their own money when trading. (10% Shareholders and Board Members are often fund managers managing other people’s money.) As such, insider trades made by Officers are much more significant and should be treated appropriately.
Like the Insider Sentiment Score, the Officer Sentiment Score is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of officer accumulation.
Update Frequency: Daily
See Insiders Top Picks, which provides a list of companies with highest insider sentiment.
Key Insider Metrics
This card shows how the company ranks along various insider metrics. The percentile rank shows how this company compares to other companies in the US markets. Higher rankings are indicative of better situations.
For example, it is generally accepted that insider buying is a positive indicator, so companies with more insider buying would rank higher than companies with less insider buying (or even insider selling).
Insider Trading Chart
Nutra Pharma Corp. insider trades are shown in the following chart. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on material, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Roster and Profitability Metrics
This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings. Additionally, when possible we provide the historical trade performance for the insider. The historical trade performance is a weighted average of the performance of actual open-market purchase transactions made by the insider. For more information on how this is calculated, watch this YouTube webinar.
See our leaderboard of most profitable insider traders.
| Insider | Avg Profit (%) | Shares Owned |
Split Adjusted |
|---|---|---|---|
| Rik J Deitsch President, CEO, Director - [D] [O] | 12,000,000 | 12,000,000 | |
| Stewart Alan Lonky Director - [D] | 20,220,000 | 505,500 |
| Insider | Avg Profit (%) | Shares Owned |
Split Adjusted |
|---|---|---|---|
| Dan Oran Director - [D] | 17,212,458 | 17,212,458 | |
| Garry Pottruck Director - [D] | 17,815,000 | 445,375 |
| Insider | Avg Profit (%) | Shares Owned |
Split Adjusted |
|---|---|---|---|
| Harold Henry Rumph President - ReceptoPharm, Director - [D] [O] | 35,000,000 | 875,000 | |
| Bruno Sartori - | 240,000 | 6,000 |
Report errors via our new Insider Auditing Tool
Track Records of Insider Purchases - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made in NPHC / Nutra Pharma Corp.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical .
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Track Records of Insider Sales - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in NPHC / Nutra Pharma Corp.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical .
The following table shows the most recent open market sales that were not part of an automatic trading plan.
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Transaction History
Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.
| File Date |
Trade Date |
Form | Insider | Ticker | Security Title | Code | Direct | Exercise Price |
Unit Price |
Units Changed |
Value Changed (1K) |
Remaining Options |
Remaining Shares |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-14 | 2021-11-15 | 5 | DEITSCH RIK J | NPHC | Series B Preferred Stock | D | 9,000,000 | 12,000,000 | ||||||
| 2022-01-14 | 2021-11-15 | 5 | DEITSCH RIK J | NPHC | Series B Preferred Stock | D | 3,000,000 | 3,000,000 | ||||||
| 2018-06-26 | 2017-10-30 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Series A Preferred | D | 0.1330 | 3,000,000 | 399 | 3,000,000 | ||||
| 2018-06-26 | 2016-12-19 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp Common Stock | D | 0.0050 | 15,000,000 | 75 | 43,298,859 | ||||
| 2018-06-26 | 2016-07-05 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp Common Stock | D | 0.0067 | 15,000,000 | 100 | 28,298,859 | ||||
| 2018-06-26 | 2016-06-28 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp Common Stock | D | 0.0135 | 4,000,000 | 54 | 13,298,859 | ||||
| 2018-06-26 | 2015-06-13 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp Common Stock | D | 0.1850 | 4,000,000 | 740 | 9,298,859 | ||||
| 2018-06-26 | 2014-12-11 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp Common Stock | D | 0.2400 | 506,900 | 122 | 5,298,859 | ||||
| 2018-06-26 | 2014-04-10 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp Common Stock | D | 0.0800 | 1,250,000 | 100 | 4,791,959 | ||||
| 2017-05-17 | 3 | ORAN DAN | NPHC | Common Stock | D | 17,212,458 | ||||||||
| 2017-05-17 | 3 | ORAN DAN Shares owned by CSA 8411, LLC. | NPHC | Common Stock | I | 16,406,229 | ||||||||
| 2017-05-17 | 3 | ORAN DAN Shares owned by CSA 8411, LLC. | NPHC | Common Stock | I | 16,406,229 | ||||||||
| 2017-05-17 | 3 | ORAN DAN Shares owned by Dan Oran Revocable Living Trust | NPHC | Common Stock | I | 31,206,229 | ||||||||
| 2017-05-17 | 3 | ORAN DAN Shares owned by Dan Oran Revocable Living Trust | NPHC | Common Stock | I | 31,206,229 | ||||||||
| 2017-05-17 | 3 | ORAN DAN | NPHC | Common Stock | D | 17,212,458 | ||||||||
| 2014-03-28 | 2013-10-18 | 4 | Lonky Stewart Alan | NPHC | NPHC Common Stock | D | 0.0080 | 70,000 | 1 | 20,220,000 | ||||
| 2014-03-28 | 2013-03-08 | 4 | Lonky Stewart Alan | NPHC | NPHC Common Stock | D | 7,730,000 | 20,150,000 | ||||||
| 2014-03-25 | 2013-11-25 | 4 | POTTRUCK GARRY | NPHC | Nutra Pharma Corp | D | 0.0140 | 6,890,000 | 96 | 17,815,000 | ||||
| 2014-03-25 | 2012-10-18 | 4 | POTTRUCK GARRY | NPHC | Nutra Pharma Corp | D | 0.0220 | 5,500,000 | 121 | 10,925,000 | ||||
| 2014-03-25 | 2012-02-10 | 4 | POTTRUCK GARRY | NPHC | Nutra Pharma Corp | D | 0.0165 | 2,875,000 | 47 | 5,425,000 | ||||
| 2014-03-21 | 2013-11-25 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp | D | 0.0140 | 11,760,000 | 165 | 141,678,334 | ||||
| 2014-03-21 | 2013-09-09 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp | D | 0.0025 | 25,000,000 | 62 | 129,918,334 | ||||
| 2014-03-21 | 2013-06-27 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp | D | 0.0040 | 25,000,000 | 100 | 104,918,334 | ||||
| 2014-03-21 | 2012-12-19 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp | D | 0.0100 | 10,000,000 | 100 | 79,918,334 | ||||
| 2014-03-21 | 2012-12-10 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp | D | 0.0149 | 200,000 | 3 | 69,918,334 | ||||
| 2014-03-21 | 2012-10-18 | 4 | DEITSCH RIK J | NPHC | Nutra Pharma Corp | D | 0.0220 | 7,500,000 | 165 | 69,718,334 | ||||
| 2014-03-21 | 2013-11-25 | 4 | Rumph Harold Henry | NPHC | Nutra Pharma Corp | D | 0.0140 | 7,400,000 | 104 | 35,000,000 | ||||
| 2014-03-21 | 2013-09-09 | 4 | Rumph Harold Henry | NPHC | Nutra Pharma Corp | D | 0.0025 | 14,800,000 | 37 | 27,600,000 | ||||
| 2014-03-21 | 2012-10-18 | 4 | Rumph Harold Henry | NPHC | Nutra Pharma Corp | D | 0.0220 | 5,000,000 | 110 | 12,800,000 | ||||
| 2014-03-21 | 2012-02-10 | 4 | Rumph Harold Henry | NPHC | Nutra Pharma Corp | D | 0.0165 | 4,000,000 | 66 | 7,800,000 | ||||
| 2014-03-21 | 2010-04-09 | 4 | Rumph Harold Henry | NPHC | Nutra Pharma Corp | D | 0.3900 | -400,000 | -156 | 3,800,000 | ||||
| 2013-03-28 | 2012-10-18 | 4 | Lonky Stewart Alan | NPHC | NPHC Common Stock | D | 5,000,000 | 12,420,000 | ||||||
| 2012-09-11 | 2012-08-30 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0110 | -303,990 | -3 | 240,000 | ||||
| 2012-09-11 | 2012-06-01 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0130 | 8,100 | 0 | 486,100 | ||||
| 2012-09-11 | 2012-05-31 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0130 | 10,000 | 0 | 478,000 | ||||
| 2012-09-11 | 2012-05-30 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0150 | 8,000 | 0 | 468,000 | ||||
| 2012-09-11 | 2012-05-22 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0110 | 7,000 | 0 | 460,000 | ||||
| 2012-09-11 | 2012-04-26 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0110 | 105,000 | 1 | 453,000 | ||||
| 2012-09-11 | 2012-04-25 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0115 | 68,000 | 1 | 348,000 | ||||
| 2012-09-11 | 2012-04-24 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0135 | 10,000 | 0 | 280,000 | ||||
| 2012-09-11 | 2012-04-23 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0115 | 25,000 | 0 | 270,000 | ||||
| 2012-09-11 | 2012-04-23 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 0.0125 | 5,000 | 0 | 245,000 | ||||
| 2012-09-07 | 2012-02-10 | 4 | SARTORI BRUNO | NPHC | Common Stock | D | 240,000 | 240,000 | ||||||
| 2012-04-26 | 2012-04-23 | 4 | DEITSCH RIK J | NPHC | Common Stock | D | 1,741.8800 | 148,000 | 257,798 | 62,218,334 | ||||
| 2012-04-19 | 2012-02-10 | 4 | Lonky Stewart Alan | NPHC | Common Stock | D | 4,400,000 | 7,420,000 | ||||||
| 2012-04-17 | 2012-02-10 | 4 | DEITSCH RIK J | NPHC | Common Stock | D | 6,800,000 | 62,070,334 |
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
